Dr. Reddy’s gets USFDA nod for US launch of Doxorubicin Hydrochloride Liposome injection

DSIJ Intelligence / 17 May 2017

Dr. Reddy’s gets USFDA nod for US launch of Doxorubicin Hydrochloride Liposome injection

Dr. Reddy’s Laboratories Limited, in a BSE filing on Wednesday announced that it has received approval from the USFDA to launch Doxorubicin Hydrochloride Liposome injection for intravenous use in the US market.

Dr. Reddy’s Laboratories Limited, in a BSE filing on Wednesday announced that it has received approval from the USFDA to launch Dr. Reddy’s Laboratories Limited for intravenous use in the US market.

The USFDA approval is an outcome of extensive collaboration with the company’s partner, Natco Pharma Limited, on R&D and manufacturing capabilities, the company also said.

“This approval represents the first of its kind for Dr. Reddy’s in the complex depot injectables arena,” said Alok Sonig, Executive Vice President and Head of the North America generics business at Reddy’s Laboratories.

The stock of Dr. Reddy’s Laboratories closed at Rs 2731 on the BSE, up by 0.32%.

If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.